Imclone Systems Inc Watch

from SC 13D/A ~20 pages Tender and Support Agreement

from 10-Q 7 pages Compensation: Your Bi-Weekly Base Salary (Annualized at $375,000) Will Be $14,423.08. Equity: Participation in Imclone Systems' 2006 Stock Incentive Plan (The "Plan") With a Grant to You of 80,000 Stock Options Vesting Equally Over Four (4) Years (The "Options"). the Exercise Term of the Options Will Be Ten (10) Years From the Grant Date, Unless Sooner Forfeited Pursuant to the Terms of the Plan. Pursuant to the Plan, the Exercise Price of the Options Is Determined by the Closing Price of the Stock on the Date Your Employment Commences With the Company. the Options Will Be Non-Qualified Stock Options. Your Grant Will Be in Accordance With the Plan, Including the Change in Control Provision in Article XI of the Plan. Except as Otherwise Provided Herein, the Options Shall Be Governed by the Terms of the Plan. Annual Bonus: You Are Eligible to Receive an Annualized Bonus for 2008. the Current Target Bonus Range for Your Position Is 38 to 43 Percent. Bonuses Are Granted at the Discretion of the Board of Directors and Are Based on Factors That Include, but Are Not Limited To, the Financial Performance of the Company, as Well as the Performance of the Individual Employee. Benefits: You Are Eligible to Participate in Imclone Systems' Comprehensive Health Plan Including Major Medical, Hospitalization, Dental and Vision Insurance Through the Company's Health Insurance Provider, Which at This Time Is Aetna. Short-Term and Long-Term Disability Insurance. Life Insurance in the Amount of Two-Times Your Annual Salary, Up to a Maximum of $400,000. You May Purchase Up to Five-Times Your Annual Salary, to a Maximum of $500,000 by Participating in Our Voluntary Life Insurance Program. You Are Eligible to Participate in the 401(k) Employee Savings Plan. You Are Eligible to Participate in the Employee Stock Purchase Plan (Espp). One-Hundred Sixty (160) Hours of Vacation Time, Subject to the Terms and Conditions of Imclone Systems' Vacation Policy

from 10-K 14 pages Amended and Restated License Agreement

from 10-K 21 pages Settlement Agreement and Mutual Release

from 10-K 5 pages This Letter Agreement (This “Agreement”) Is Intended to Clarify the Rights and Responsibilities of Merck Kgaa, a German Corporation With General Partners (“Merck”), Merck Serono Japan Company, Limited, a Japanese Corporation (“Mj”), and Imclone Systems Incorporated, a Delaware Corporation (“Imclone”), Under the Japan Agreement and Under That Certain Development and License Agreement, Dated December 14, 1998, Between Merck and Imclone (As Such Agreement Has Been Amended, Modified and Supplemented, the “Existing Agreement”) With Respect to Japan in Light of Their Entry Into the Japan Agreement. This Agreement Shall Become Effective Upon the Signing of the Japan Agreement by All of the Parties Thereto (The “Effective Date”). Unless Otherwise Indicated, Initially Capitalized Terms Shall Have the Meanings Given to Them in the Japan Agreement. 1. Royalties for Japan; Other Matters Under Japan Agreement

from 10-K 17 pages Bms-Imclone Japan Agreement

from 10-K 117 pages Amended and Restated Co-Development and Co-Commercialization Agreement for Erbitux ® in Japan Among

from 10-Q 16 pages Employment Agreement

from 10-Q 42 pages Amendment No. 2 to Development, Promotion, Distribution and Supply Agreement

from 10-K 4 pages Letter Agreement

from 10-K 26 pages Imclone Systems Incorporated 2006 Stock Incentive Plan

from 10-Q 26 pages Settlement Agreement

from 10-K/A 9 pages March 21, 2006 Mr. Joseph L. Fischer 61 Lake Road Far Hills, Nj 07931 Dear Joe, the Purpose of This Letter (The “Letter Agreement”) Is to Set Forth Our Agreement With Respect to Your Employment With Imclone Systems Incorporated (“Imclone”) as Its Interim Chief Executive Officer, Which Position You Assumed on January 24, 2006 (The “Effective Date”)

from S-8 11 pages Imclone Systems Incorporated 2005 Inducement Stock Option Plan

from 10-K 17 pages Imclone Systems Incorporated Transition Severance Plan Effective as of March 1, 2006

from 10-K 19 pages Imclone Systems Incorporated Change-In-Control Plan

from 8-K 6 pages Imclone Systems Incorporated 2006-2008 Retention Plan

from 8-K 2 pages Imclone Systems Incorporated 180 Varick Street New York, Ny 10014 December 21, 2005

from 10-Q 143 pages Collaboration and Licence Agreement Dated 15 August 2005 Among Ucb S.A. and Imclone Systems Incorporated Contents

from 8-K 11 pages Imclone Systems Incorporated 2005 Inducement Stock Option Plan